Transfusion alternatives in transfusion medicine : TATM最新文献_第7页

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-09-01 DOI: 10.1111/J.1778-428X.2008.00117.X

R. Cardigan, S. Maclennan

{"title":"Allogeneic blood components","authors":"R. Cardigan, S. Maclennan","doi":"10.1111/J.1778-428X.2008.00117.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2008.00117.X","url":null,"abstract":"SUMMARY \u0000 \u0000 \u0000There are no absolute recognized clinical indications for the transfusion of whole blood, and therefore blood is separated into its components (red cells, platelets and plasma) prior to transfusion. Blood components can be either produced from whole-blood donations or collected directly from the donor by apheresis technology. In many countries, blood components are depleted of leukocytes prior to storage. There are several potential benefits of leukocyte depletion including reduced immune complications and transfusion transmission of some cell-associated viruses [e.g. cytomegalovirus (CMV)]; however, in the UK a perceived benefit in terms of reducing the risk of transmission of variant Creutzfeldt-Jakob disease (vCJD) was a key factor in recommending its implementation. In the developed world, the risk of blood components transmitting infection is low because of stringent donor selection and testing criteria. These risks can be reduced further by the use of pathogen inactivation systems. Systems are now licensed and in use in some European countries for pathogen inactivation of plasma and platelet components; systems for red cells are not yet available. Recently, filters designed to remove prion protein from red cells have been developed with the aim of reducing the risk of transmission of vCJD by blood, and these are under assessment in the UK. As yet, there are no filters available to remove prion protein from plasma, platelets or whole blood.","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":"41 1","pages":"92-101"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2008.00117.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63389662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

The Limits of Bloodless Surgery 无血手术的局限性

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-28 DOI: 10.1111/J.1778-428X.2005.TB00124.X

J. Carson

引用次数: 4

Recognizing Transfusion Reactions In The Pediatric Population 认识儿科人群中的输血反应

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-28 DOI: 10.1111/j.1778-428X.2006.tb00197.x

Frcpc

引用次数: 0

Reevaluating Our Approches to Acute and Chronic Anemias 重新评估我们治疗急慢性贫血的方法

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-28 DOI: 10.1111/J.1778-428X.2005.TB00118.X

L. Goodnough

引用次数: 0

Anemia in Patients With Cancer or Undergoing Cancer Therapy: Impact and Current Treatment Practice 癌症或接受癌症治疗的患者贫血:影响和目前的治疗实践

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-28 DOI: 10.1111/J.1778-428X.2005.TB00120.X

D. Henry

{"title":"Anemia in Patients With Cancer or Undergoing Cancer Therapy: Impact and Current Treatment Practice","authors":"D. Henry","doi":"10.1111/J.1778-428X.2005.TB00120.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2005.TB00120.X","url":null,"abstract":"SUMMARY \u0000 \u0000Anemia is a multifactorial and global problem in cancer patients and negatively impacts quality of life (QOL) and treatment outcomes. This article provides an update on several aspects of anemia, including its etiology, prevalence, and broad impact; goals of anemia treatment; available treatment options; published treatment guidelines; and future areas of investigation, with the aim of providing information to guide optimal anemia management in cancer patients. Based on clinical practice and trial data over the last decade, treatment with epoetin alfa 150–300 U/kg three times weekly or 40,000–60,000 U once weekly (QW) results in mean hemoglobin (Hb) increases of μ1 g/dL after 4 weeks and μ2 g/dL after 8 weeks that are associated with significant reductions in transfusion requirements and QOL improvements in anemic cancer patients. Darbepoetin alfa 2.25-4.5 μg/kg QW or 3.0–5.0 μg/kg every 2 weeks results in mean Hb increases of μ1.5 g/dL by end of treatment and significantly reduces transfusion requirements; QOL endpoints are promising. Ultimately, anemia treatment should be guided by experience and anemia treatment guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN) and the American Society of Hematology/American Society of Clinical Oncology (ASH/ASCO).","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":"6 1","pages":"14-25"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2005.TB00120.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63386653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Anemia and Blood Transfusion in the Critically Ill Patient 危重病人贫血与输血

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-28 DOI: 10.1111/J.1778-428X.2005.TB00122.X

H. Corwin

{"title":"Anemia and Blood Transfusion in the Critically Ill Patient","authors":"H. Corwin","doi":"10.1111/J.1778-428X.2005.TB00122.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2005.TB00122.X","url":null,"abstract":"SUMMARY \u0000 \u0000Anemia is common in critically ill patients and results in a large number of red blood cell (RBC) transfusions. Recent data from both the US and Europe confirm that transfusion practice has changed little over the last decade. Between 40 and 50% of all patients admitted to intensive care units (ICU) receive at least one RBC unit and average close to 5 RBC units during their ICU admission. In these patients, extent of anemia is associated with poorer clinical outcomes, however RBC transfusion appears not to improve these outcomes.The anemia of critical illness is a distinct clinical entity characterized by a blunted erythropoietin (EPO) production and abnormalities in iron metabolism identical to what is commonly referred to as the anemia of chronic disease.There is little evidence that “routine” transfusion of stored allogeneic RBCs is beneficial to critically ill patients. It is clear that most critically ill patients can tolerate hemoglobin levels as low as 7 g/dL, and therefore a more conservative approach to RBC transfusion is warranted. Strategies to minimize blood loss and increase the production of RBCs are important in the management of all critically ill patients.","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":"6 1","pages":"38-42"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2005.TB00122.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63386704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Anemia in Chronic Kidney Disease Patients 慢性肾病患者的贫血

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-28 DOI: 10.1111/J.1778-428X.2005.TB00119.X

A. Rastogi, A. Nissenson

引用次数: 8

Erythropoietin and Iron 促红细胞生成素和铁

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-28 DOI: 10.1111/J.1778-428X.2005.TB00125.X

L. Goodnough

引用次数: 0

Tolerance of Acute Anemia: The Anesthesiology Perspective 急性贫血的耐受性:麻醉学的观点

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-28 DOI: 10.1111/J.1778-428X.2005.TB00123.X

A. Shander, Tanuja S. Rijhwani, Petra Seeber

{"title":"Tolerance of Acute Anemia: The Anesthesiology Perspective","authors":"A. Shander, Tanuja S. Rijhwani, Petra Seeber","doi":"10.1111/J.1778-428X.2005.TB00123.X","DOIUrl":"https://doi.org/10.1111/J.1778-428X.2005.TB00123.X","url":null,"abstract":"SUMMARYAnesthesiologists have to face anemia in a variety of surgical interventions and have had the challenge of assuring positive patient outcomes. As such, treatment of acute anemia has traditionally resulted in increased exposure to allogeneic blood transfusions. Enhancing our knowledge of the hemoglobin molecule, its functions and reserve, allows the anesthesiologist to utilize compensatory mechanisms to achieve a positive outcome, with the reduction or elimination of patient's exposure to allogeneic blood transfusions. Since the inception of anesthesiology as a medical specialty, one of the most important issues for anesthesiologists has been oxygen delivery and consumption. Anemia has been a long-time challenge for the anesthesiologist. Anemia is defined as a decline of hemoglobin concentration or hematocrit. During acute normovolemic anemia, compensatory mechanisms are elicited at both the macrocirculatory (systemic) and microcirculatory level. Acute normovolemic hemodilution (ANH) is the intentional dilution of blood (a state of anemia) caused by controlled withdrawal of surgical patient's blood for reinfusion within 8 hours during and following surgical blood loss. This technique provides fresh whole blood for transfusion and avoids the pitfalls of predonated blood. ANH is an iatrogenic condition where dilutional anemia is used to the advantage of a patient for blood conservation, i.e. as an alternative for allogeneic blood transfusion. The effects of ANH-induced anemia on various organ systems and functions are discussed in addition to the effect of anesthesia and anesthetic depth.","PeriodicalId":90375,"journal":{"name":"Transfusion alternatives in transfusion medicine : TATM","volume":"6 1","pages":"43-51"},"PeriodicalIF":0.0,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/J.1778-428X.2005.TB00123.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"63386720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Approaches to treating chronic anemia in developing countries 发展中国家治疗慢性贫血的方法

Transfusion alternatives in transfusion medicine : TATM Pub Date : 2008-06-01 DOI: 10.1111/J.1778-428X.2008.00106.X

K. Phiri

引用次数: 6